Role of islatravir in HIV treatment and prevention: an update

Risks and benefits of reducing the number of drugs to treat HIV-1 infection

(2021) Julen Cadiñanos et al.   Expert Opinion On Drug Safety

Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir

(2021) Bluma G Brenner et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial

(2021) Jean-Michel Molina et al.   Lancet HIV

Development of Human Immunodeficiency Virus Type 1 Resistance to 4’-Ethynyl-2-Fluoro-2’-Deoxyadenosine (EFdA) Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor Resistant-Strains

(2021) Maria E. Cilento et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV

(2021) Randolph P. Matthews et al.   CLINICAL DRUG INVESTIGATION

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV

(2021) Randolph P. Matthews et al.   CTS-Clinical and Translational Science

Safety and Pharmacokinetics of Once-Daily Multiple-Dose Administration of Islatravir in Adults Without HIV

(2021) Randolph P. Matthews et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Effects of islatravir (4′-ethynyl-2-fluoro-2′-deoxyadenosine or EFdA) on renal tubular cells and islatravir's interactions with organic anion transporters

(2021) Meika Kaneko et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters

(2021) Kelly Bleasby et al.   Viruses-Basel

Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial

(2021) Randolph P. Matthews et al.   NATURE MEDICINE

Lack of a Clinically Meaningful Drug Interaction Between the HIV‐1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate

(2021) Deanne Jackson Rudd et al.   Clinical Pharmacology in Drug Development

Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial

(2020) Dirk Schürmann et al.   Lancet HIV

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2020) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Drug–drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment

(2019) Dario Cattaneo et al.   Expert Opinion on Drug Metabolism & Toxicology

Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3

(2019) Martin Markowitz et al.   JOURNAL OF INFECTIOUS DISEASES

Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1

(2019) Martin Markowitz et al.   Current Opinion in HIV and AIDS

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

(2018) Josep M Llibre et al.   LANCET

4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591

(2018) Martin Markowitz et al.   Current Opinion in HIV and AIDS

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA

(2017) Maureen Oliveira et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA)

(2016) Zhe Li Salie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054)

(2015) Benoit Trottier et al.   HIV CLINICAL TRIALS

4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms

(2014) Eleftherios Michailidis et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The end of AIDS: HIV infection as a chronic disease

(2013) Steven G Deeks et al.   LANCET

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

(2013) Ulrich M. Zanger et al.   PHARMACOLOGY & THERAPEUTICS

Development of Antiretroviral Drug Resistance

(2011) Mark A. Wainberg et al.   NEW ENGLAND JOURNAL OF MEDICINE